TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00556166

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enterra Therapy Gastric Stimulator
Description: The intramuscular stomach leads, implanted in a minimally invasive surgical procedure lasting 1-3 hours, are placed on the greater curvature of the stomach. The implanted pulse generator (IPG) is about 2 1/2 x 2 x 1/2 and is implanted in a subcutaneous pocket, generally created in the abdominal area, and is then connected to the leads. The IPG provides the energy source that delivers the electrical pulse to the stomach muscle through the stomach leads to improve the symptoms of gastroparesis.~The doctor will use an external programmer to change the settings of the neurostimulator and control the neurostimulator after implantation. Part of the programmer is held outside the body over the implant site and can adjust or change the settings of the neurostimulator using radio remote control.
Study: NCT03286595

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobi mHealth app
Description: Mobile application (i.e. the app) that patients interact with via their smartphone to collect daily and weekly survey information. Data is visualized on a clinician-facing Dashboard, which can be used to inform treatment.
Study: NCT01994395

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Impairment based therapy
Description: Participants participate in 18 weeks of outpatient physical therapy + 3 assessment sessions. Assessment (strength, flexibility, balance, sensation, endurance, transfers, gait). Treatment will be divided into: 15 min balance training, 15 minutes functional mobility (transfers, strength or flexibility training) and 15 min high intensity gait training
Study: NCT01548690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ornithine Phenylacetate
Description: Up to 36 patients will be enrolled into 2 groups \[\~18 with minimal renal dysfunction (Cohort 1) \& \~18 w/ comprised renal function (Cohort 2)\] and receive OCR-002 infusion for at least 72 hrs. OCR-002 will be administered in the vein and pharmacokinetics (pk) assessed for all subjects who receive the infusion.~The first 24 enrolled subjects received OCR-002 at 3 ascending dose levels (DLs 1-3) with a maximum target infusion rate equivalent to 10g/24h.~The remaining 12 patients (\~6 Cohort 1 \& \~6 Cohort 2) will be enrolled and receive identical quantities of OCR-002 at 20g/24hr continuously for 5 days (Dose Level 4).
Study: NCT01626976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06282999
Description: Solution, doses range from 20 to 200 mg, single dose
Study: NCT02641730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Participants will receive two or one syringe of guselkumab 100 mg subcutaneously at Week 0, 4, 12 and every 8 weeks thereafter through Week 60 in group 1 or 2. Group 3a or 3b participants will receive two or one syringe of guselkumab 100 mg at Week 16, 20 and every 8 weeks thereafter through Week 60.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Participants will receive two or one syringe of guselkumab 100 mg subcutaneously at Week 0, 4, 12 and every 8 weeks thereafter through Week 60 in group 1 or 2. Group 3a or 3b participants will receive two or one syringe of guselkumab 100 mg at Week 16, 20 and every 8 weeks thereafter through Week 60.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Participants will receive two or one syringe of guselkumab 100 mg subcutaneously at Week 0, 4, 12 and every 8 weeks thereafter through Week 60 in group 1 or 2. Group 3a or 3b participants will receive two or one syringe of guselkumab 100 mg at Week 16, 20 and every 8 weeks thereafter through Week 60.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants in group 1 will receive placebo at Week 16. Participants in group 2 will receive placebo at Week 0, 4, 12, 16, 20 and every 8 weeks thereafter through Week 60. Participants in group 3 will receive placebo at Week 0, 4, 12, then at Week 16, 20 and every 8 weeks thereafter through Week 60 for group 3b.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants in group 1 will receive placebo at Week 16. Participants in group 2 will receive placebo at Week 0, 4, 12, 16, 20 and every 8 weeks thereafter through Week 60. Participants in group 3 will receive placebo at Week 0, 4, 12, then at Week 16, 20 and every 8 weeks thereafter through Week 60 for group 3b.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants in group 1 will receive placebo at Week 16. Participants in group 2 will receive placebo at Week 0, 4, 12, 16, 20 and every 8 weeks thereafter through Week 60. Participants in group 3 will receive placebo at Week 0, 4, 12, then at Week 16, 20 and every 8 weeks thereafter through Week 60 for group 3b.
Study: NCT01350609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine/Candesartan (BAY 98-7106)
Description: Fixed dose combination of 60 mg nifedipine + 32 mg candesartan (1 tablet in one period)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine (Adalat, BAY A1040) and Candesartan (Atacand, BAY 12-9333)
Description: Loose combination of 1 tablet nifedpipine 60mg (Adalat LA) and 2 tablets candesartan 16mg (Atacand) (3 tablets in one period) .
Study: NCT02601326

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic ventral mesh Rectopexy
Description: Laparoscopic fixation of rectum to sacral promontory using mesh

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delorme's procedure
Description: Transanal excision of rectal mucosa and plication of muscle layer
Study: NCT04625634

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2 days of work heat stress
Description: 2 consecutive days of identical simulated structural firefighting tasks.
Study: NCT03054168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sustanon 250
Description: The frequency of the injection will be every 2 weeks, 250mg of testosterone, intramuscular injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoladex
Description: The frequency of the injection will be just one injection, 3.6 mg of Zoladex, Subcutaneous injection (abdomen).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT05209139

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot juice
Description: One serving 70 mL of beetroot juice (6.4 mmol of NO3-; Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) 3 h before initiating the testing session.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Beetroot juice
Description: One serving 70 mL of beetroot juice (6.4 mmol of NO3-; Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) 3 h before initiating the testing session.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot juice placebo
Description: One serving 70 mL of beetroot juice placebo (0.04 mmol of NO3-; Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) 3 h before initiating the testing session.
Study: NCT03307252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: Oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: Oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: Oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: Oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: Oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: Oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: Oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cimetidine
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cimetidine
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probenecid
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probenecid
Description: Tablet
Study: NCT01657838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isavuconazole
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isavuconazole
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: oral
Study: NCT00998504

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: resVida
Description: resVida or placebo will be given for 30 days, twice daily. One pill, which contains 75 mg of resVida, will be provided with lunch, and the other pill will be provided with diner. So in total, 150 mg/day will be given.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: resVida or placebo will be given for 30 days, twice daily. One pill, which contains 75 mg of resVida, will be provided with lunch, and the other pill will be provided with diner. So in total, 150 mg/day will be given.
Study: NCT02499848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRX302
Description: Single prostate cancer lesion injected with PRX302.
Study: NCT03124277

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fortifit®
Description: Best local diet + two servings (40 grams each) of powder (Fortifit®; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, 800 IU vitamin D, and a mixture of vitamins, minerals, and fibers.

Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: Best local diet
Study: NCT03246451

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: 2-4 tablets in 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 1000-2000 mg in 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: 9 mg/ml saline infusion during experimental days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exendin (9-39)
Description: Infusion of GLP-1 receptor antagonist used as a tool during experimental days
Study: NCT05209139

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Beetroot juice placebo
Description: One serving 70 mL of beetroot juice placebo (0.04 mmol of NO3-; Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) 3 h before initiating the testing session.
Study: NCT04166786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone gel
Description: Subjects receive a daily transdermal dose of 100 mg of testosterone (2 sachets of 5 g of gel) during 3 days.

Intervention type: DRUG
Group type: OTHER
Intervention: Testosterone gel
Description: Subjects receive a daily transdermal dose of 100 mg of testosterone (2 sachets of 5 g of gel) during 3 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanol Solution
Description: Subjects receive a daily administration of 30 g of ethanol (94 mL of Vodka Absolut® diluted in 300 mL of lemon-flavoured water Fontvella®) during 3 days.

Intervention type: DRUG
Group type: OTHER
Intervention: Ethanol Solution
Description: Subjects receive a daily administration of 30 g of ethanol (94 mL of Vodka Absolut® diluted in 300 mL of lemon-flavoured water Fontvella®) during 3 days.

Intervention type: DRUG
Group type: OTHER
Intervention: Testosterone placebo (vaseline)
Description: Subjects receive a daily transdermal dose of 5 g of pure vaseline ointment during 3 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Testosterone placebo (vaseline)
Description: Subjects receive a daily transdermal dose of 5 g of pure vaseline ointment during 3 days.

Intervention type: DRUG
Group type: OTHER
Intervention: Ethanol placebo (lemon-flavoured water)
Description: Subjects receive a daily administration of 394 mL of lemon-flavored-water Fontvella® during 3 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ethanol placebo (lemon-flavoured water)
Description: Subjects receive a daily administration of 394 mL of lemon-flavored-water Fontvella® during 3 days.
Study: NCT01087918

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RAGT
Description: 16 sessions / 4 times/week / 45 minutes Lokomat training

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RAGT
Description: 16 sessions / 4 times/week / 45 minutes Lokomat training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength Training
Description: 16 sessions / 4 times/week / 45 minutes lower extremity strength training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength Training
Description: 16 sessions / 4 times/week / 45 minutes lower extremity strength training
Study: NCT01628731

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: furosemide
Description: furosemide, intravenous, continuous infusion, 0.2 mg/kg/h for 24 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ethacrynic acid
Description: ethacrynic acid, intravenous, continuous infusion, 0.2 mg/kg/h for 24 hours
Study: NCT03247569

Intervention type: DRUG
Intervention: Edoxaban
Description: Edoxaban according to Package Information (Summary of Product Characteristics (SmPC)).
Study: NCT01626976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Solution, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06282999
Description: Methylcellulose suspension, doses range 125 to 500 mg, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: suspension, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06282999
Description: Methylcellulose or simethicone suspension, doses range 200 to 500 mg, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: suspension, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06282999
Description: Methylcellulose or simethicone suspension, 500 mg dose, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: suspension, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06282999
Description: Simethicone or methylcellulose suspension, up to 1500 mg, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: suspension, single dose
Study: NCT01940705

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hearing-Aid Informational Guide
Description: Printed take-home guide on hearing aids

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hearing-Aid DVD
Description: Take-home DVD about hearing aids

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teach-back Technique
Description: Counseling/Educational session using the teach-back technique to review information about their hearing aids
Study: NCT03533335

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral spray (chlorhexidine spray, chlorine dioxide spray, sterile water spray)
Description: Application of a daily dose of 12 sprays (each delivering a volume of 0.13ml) to the buccal and lingual gingival third of tooth surfaces in each sextant

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral spray (chlorhexidine spray, chlorine dioxide spray, sterile water spray)
Description: Application of a daily dose of 12 sprays (each delivering a volume of 0.13ml) to the buccal and lingual gingival third of tooth surfaces in each sextant

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oral spray (chlorhexidine spray, chlorine dioxide spray, sterile water spray)
Description: Application of a daily dose of 12 sprays (each delivering a volume of 0.13ml) to the buccal and lingual gingival third of tooth surfaces in each sextant
Study: NCT02392559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Dose of subcutaneous evolocumab every 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose of subcutaneous placebo treatment every 4 weeks
Study: NCT03176511

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A Matter of Balance plus Dual-Task Balance Challenge Group
Description: Participants will receive the standard MOB classes, along with a 15-min DTBC each class, i.e., right and left foot ankle-reaching to three differently colored markers. Three colored dots are placed on the ground in an arc, using different colored stick-on dots. A chair can be placed in front of the color pattern, as needed for safety.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: A Matter of Balance Group
Description: Participants will receive the standard MOB class, taught by a certified MOB, using course materials developed by MaineHealth's Partnering for Healthy Aging (http://www.mainehealth.org/pfha).
Study: NCT01516684

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo administration
Description: Given topically

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMLA
Description: Given topically

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fentanyl citrate
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl citrate
Description: Given IV
Study: NCT04661163

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: Virtual Reality Avatar Therapy is a psychotherapeutic intervention targeting auditory hallucinations
Study: NCT03797378

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eM2M
Description: The eM2M intervention involves three 60-minute sessions per week for 12 weeks. All sessions are delivered remotely in real-time through videoconferencing technology. The intervention uses combinations of movement patterns that target range of motion, muscle strength, cardiorespiratory fitness, balance, and breathing. Each session consists of movement routines choreographed to music, and every routine can be adapted to participants' functional ability.
Study: NCT02174549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirapazamine
Description: Intra-arterial injection into the tumor feeding artery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Transarterial Embolization (TAE)
Description: Lipiodol and Gelfoam used to embolize tumor vessels and induce tumor hypoxia
Study: NCT03594175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CUSA-081
Description: Participants received 1 or 2 doses of CUSA-081 0.7 mg/2 mL directly into the catheter lumen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received 1 or 2 doses of placebo (normal saline) directly into the catheter lumen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alteplase
Description: Participants received 1 or 2 doses of alteplase, 2 mg/2 mL, directly into the catheter lumen
Study: NCT03413722

Intervention type: DRUG
Intervention: Tacrolimus
Description: The patient's physician will prescribe drug according to standard practice.

Intervention type: DRUG
Intervention: Tacrolimus
Description: The patient's physician will prescribe drug according to standard practice.

Intervention type: DRUG
Intervention: Everolimus
Description: The patient's physician will prescribe drug according to standard practice.
Study: NCT04112667

Intervention type: OTHER
Intervention: Normal Macular Health
Description: This group of participants will have function assessed using rod- and cone-mediated tests (rod-mediated dark adaptation, 2 color dark adapted perimetry, cone-mediated perimetry, photopic and mesopic acuity, photopic and mesopic contrast sensitivity). Age-related macular degeneration status will be determined by multi-modal imaging.

Intervention type: OTHER
Intervention: Early Macular Degeneration
Description: This group of participants will have function assessed using rod- and cone-mediated tests (rod-mediated dark adaptation, 2 color dark adapted perimetry, cone-mediated perimetry, photopic and mesopic acuity, photopic and mesopic contrast sensitivity). Age-related macular degeneration status will be determined by multi-modal imaging.

Intervention type: OTHER
Intervention: Young Normals
Description: This group of participants will have function assessed using rod- and cone-mediated tests (rod-mediated dark adaptation, 2 color dark adapted perimetry, cone-mediated perimetry, photopic and mesopic acuity, photopic and mesopic contrast sensitivity). Age-related macular degeneration status will be determined by multi-modal imaging.
Study: NCT01940705

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: standard of care hearing-aid orientation as provided by clinical audiologist

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: standard of care hearing-aid orientation as provided by clinical audiologist

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: standard of care hearing-aid orientation as provided by clinical audiologist

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: standard of care hearing-aid orientation as provided by clinical audiologist
Study: NCT01108744

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hypertonic saline
Description: 3% hypertonic saline, dosed by ideal patient weight

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mannitol
Description: Mannitol 20% intravenous solution, dosed by patient's ideal body weight